Semaglutide

Semaglutide - GLP-1 Receptor Agonist Research Peptide

Semaglutide is a long-acting synthetic analog of GLP-1 (glucagon-like peptide-1), a gut hormone the body releases after a meal. It is the active molecule in Ozempic, Wegovy, and Rybelsus, all developed by Novo Nordisk. Because it was one of the first GLP-1 peptides designed for once-weekly administration, semaglutide has the longest and most complete body of published clinical and preclinical literature of any compound in this class, which makes it the standard reference point in metabolic and obesity research.

Why GLP-1 Agonism Matters

Native GLP-1 has a half-life of roughly 2 minutes, which makes it useless as a research tool. Semaglutide was engineered with a fatty-acid side chain that binds reversibly to albumin, protecting the peptide from enzymatic breakdown and extending its half-life to about a week. That lets researchers maintain steady receptor occupancy on a once-weekly administration schedule instead of chasing the hormone with daily or continuous delivery.

Semaglutide vs Tirzepatide vs Retatrutide

The three peptides researchers compare most often all sit on the same GLP-1 lineage but hit different receptor combinations.

Head-to-head trial data reported in the New England Journal of Medicine (Jastreboff et al., 2022) showed tirzepatide produced larger weight-loss endpoints than semaglutide in equivalent-length studies, and retatrutide reported even larger endpoints in Phase 2. Semaglutide remains the most-studied and most-published reference compound in the class.

Research Applications

Semaglutide is used in studies examining:

• Body-composition changes across caloric-restriction models
• Glycemic control and insulin sensitivity in metabolic models
• Appetite, satiety, and food-reward pathways in feeding-behavior research
• Cardiovascular markers under sustained GLP-1 agonism (the SELECT trial framework)
• Dose-response curves during stepwise titration
• Reference comparisons against newer dual- and triple-agonist peptides

Specifications

Storage & Handling

Unopened vials are kept at 2-8°C under standard cold-chain conditions and remain stable for 12+ months. Reconstitution parameters, solvent compatibility, and post-reconstitution stability for Semaglutide are documented in the published peer-reviewed literature and standard peptide-chemistry references.

Reference Literature

Published clinical and preclinical Semaglutide literature is available through PubMed, Google Scholar, and other peer-reviewed databases. WWP does not provide protocol design, dosing guidance, or administration parameters. Those decisions rest with the researcher and any applicable institutional review board.

Common Questions About Semaglutide Research

Is semaglutide the same as Ozempic?

Semaglutide is the active peptide; Ozempic and Wegovy are Novo Nordisk’s brand-name injectable products that contain it. Rybelsus is the oral tablet version. The underlying molecule is the same across all three commercial products - what differs is the formulation and the approved dose range. Research-grade semaglutide from WWP is the peptide on its own in lyophilized form.

What is the difference between semaglutide and tirzepatide?

Semaglutide activates one receptor (GLP-1). Tirzepatide activates GLP-1 and GIP. In head-to-head trials (SURMOUNT-5 and others), tirzepatide produced larger body-composition changes at equivalent study durations. Semaglutide’s body of published data is considerably larger, which is why it remains the reference compound in most GLP-1 studies.

What does semaglutide do in metabolic studies?

It activates GLP-1 receptors across four tissues: pancreas (glucose-dependent insulin release, glucagon suppression), stomach (slowed gastric emptying), and hypothalamus (appetite signaling). Study endpoints most commonly reported are changes in HbA1c, fasting glucose, ad-libitum caloric intake, and body-composition markers.

Is semaglutide FDA approved?

Brand-name formulations (Ozempic, Wegovy, Rybelsus) are FDA approved for specific clinical indications. Research-grade semaglutide sold by WWP is not a branded drug product and is not approved or intended for human consumption. Every vial is labeled and sold strictly for laboratory and research use only.

How is semaglutide stored?

Unopened vials are stored at 2-8°C (refrigerator temperature) and stay stable for 12+ months. Once reconstituted with bacteriostatic water, the solution is kept at 2-8°C and used within 28-30 days.

Purity Guarantee

Every batch is ≥99% purity. Send us a COA from any independent test and we’ll issue store credit regardless of what it shows.